Surge

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of therandomized phase III EORTC 40983 Intergroup study, or EPOC study,demonstrate for the first time that peri-operative (pre and postsurgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) incombination with a standard chemotherapy regimen for co...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...

ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 17, 2007 - Artes Medical, Inc.(Nasdaq:ARTE), a medical technology company focused on developing,manufacturing and commercializing a new category of aestheticinjectable products for men and women, today announced that thefinal 5-year safety and efficacy data for ArteFill(R), theCompany's FDA-approved non-resorbable injectable dermal filler willbe presented at...

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg DosageLevel HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Boston Life Sciences announced today that clinical data on its leadnerve repair therapy, Cethrin(R), were presented in the Neurotraumaand Critical Care Scientific Session at the 75th Annual Meeting ofthe American Association of Neurological Surgeons (AANS) inWash...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-sponsored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...

New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health

SOMERSET, N.J., April 5, 2007-- Stent thrombosis,restenosis and lifelong prescriptions. Millions of patients havediscovered that the drug-coated stents used as part of their heartoperations may be having more of a detrimental effect on theirhealth than medical experts have ever publicly acknowledged. Recentarticles in medical journals suggest that unless patients whoreceive drug-eluting...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest SafetyProgram of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorablefindings of the investigational drug Cleviprex(TM) (clevidipine)compared to current intravenous antihypertensive agents incontrolling perioperative hypertension -- a potentially harmfulelevation in blood pressure j...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease

NEW ORLEANS, March 26, 2007 /PRNewswire-FirstCall/ -- Three-yearfollow-up data presented today at the of Cardiology's 56th AnnualScientific Session (ACC.07) showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) in patients withblockages in two or more vessels, one of the most complex patientpopulations...